Literature DB >> 11839580

Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression.

Abeer M Shaaban1, John P Sloane, Christopher R West, Christopher S Foster.   

Abstract

The hypothetical multistep model for breast carcinogenesis indicates that invasive carcinoma arises via a series of intermediate hyperplastic lesions through various grades of atypia to in situ and invasive carcinoma. Non-atypical hyperplasia [hyperplasia of usual type (HUT)] is a nonobligate precursor of breast cancer. Although its further morphological subclassification is unlikely, refining is more likely to depend on defining biological markers of risk. Having assembled a cohort of benign proliferative breast lesions of known outcome, we studied the expression of estrogen receptor-alpha (ER-alpha) and Ki-67 using morphometric image analysis as well as dual-labeled immunofluorescence in HUT foci and in surrounding normal lobules of 25 patients that progressed to breast cancer and 19 controls. Those patients that progressed to breast cancer (cases) showed significantly higher ER-alpha [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001). No significant difference in expression of dual-stained cells was found between cases and controls. Although normal lobules from cases showed higher ER-alpha expression compared with controls, this was not statistically significant. Our data point to a previously undescribed hormone-dependent pathway in this particular group of breast neoplasms and suggest the possibility of selective hormonal therapy to suppress the proliferative potential of these benign but high-risk breast lesions. The findings of this study might have important implications for improving breast cancer screening and management strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839580      PMCID: PMC1850641          DOI: 10.1016/s0002-9440(10)64879-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells.

Authors:  M Iqbal; M P Davies; B S Shoker; C Jarvis; D R Sibson; J P Sloane
Journal:  J Pathol       Date:  2001-03       Impact factor: 7.996

2.  Tamoxifen suppresses histologic progression to atypia and DCIS in MCFIOAT xenografts, a model of early human breast cancer.

Authors:  D W Visscher; P Nanjia-Makker; G Heppner; P V Shekhar
Journal:  Breast Cancer Res Treat       Date:  2001-01       Impact factor: 4.872

Review 3.  Biological and molecular bases of mammary carcinogenesis.

Authors:  J Russo; I H Russo
Journal:  Lab Invest       Date:  1987-08       Impact factor: 5.662

4.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

5.  Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast.

Authors:  G Williams; E Anderson; A Howell; R Watson; J Coyne; S A Roberts; C S Potten
Journal:  Int J Cancer       Date:  1991-05-10       Impact factor: 7.396

Review 6.  Cell proliferation in carcinogenesis.

Authors:  S M Cohen; L B Ellwein
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 7.  Anatomic markers of human premalignancy and risk of breast cancer.

Authors:  D L Page; W D Dupont
Journal:  Cancer       Date:  1990-09-15       Impact factor: 6.860

8.  Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group.

Authors:  R W McDivitt; J A Stevens; N C Lee; P A Wingo; G L Rubin; D Gersell
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

9.  A prospective study of benign breast disease and the risk of breast cancer.

Authors:  S J London; J L Connolly; S J Schnitt; G A Colditz
Journal:  JAMA       Date:  1992-02-19       Impact factor: 56.272

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

View more
  43 in total

1.  Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside.

Authors:  Carol J Fabian; Bruce F Kimler; Carola M Zalles; Jennifer R Klemp; Brian K Petroff; Qamar J Khan; Priyanka Sharma; Kenneth D R Setchell; Xueheng Zhao; Teresa A Phillips; Trina Metheny; Jennifer R Hughes; Hung-Wen Yeh; Karen A Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-19

2.  Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.

Authors:  Carol J Fabian; Bruce F Kimler; Teresa A Phillips; Jennifer L Nydegger; Amy L Kreutzjans; Susan E Carlson; Brandon H Hidaka; Trina Metheny; Carola M Zalles; Gordon B Mills; Kandy R Powers; Debra K Sullivan; Brian K Petroff; Whitney L Hensing; Brooke L Fridley; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

3.  Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Authors:  Prashant Rajbhandari; Greg Finn; Natalia M Solodin; Kiran K Singarapu; Sarata C Sahu; John L Markley; Kelley J Kadunc; Stephanie J Ellison-Zelski; Anastasia Kariagina; Sandra Z Haslam; Kun Ping Lu; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

4.  In vitro verification of the correlation of in vivo 99mTc-(V)DMSA uptake with cellular proliferation rate.

Authors:  Vassilios Papantoniou; Spyridon Tsiouris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

Review 5.  Suitable trial designs and cohorts for preventive breast cancer agents.

Authors:  Kathrin Strasser-Weippl; Paul E Goss
Journal:  Nat Rev Clin Oncol       Date:  2013-10-08       Impact factor: 66.675

6.  Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.

Authors:  Katherine D Crew; Powel Brown; Heather Greenlee; Therese B Bevers; Banu Arun; Clifford Hudis; Heather L McArthur; Jenny Chang; Mothaffar Rimawi; Lana Vornik; Terri L Cornelison; Antai Wang; Hanina Hibshoosh; Aqeel Ahmed; Mary Beth Terry; Regina M Santella; Scott M Lippman; Dawn L Hershman
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-24

7.  Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia.

Authors:  Marta Santisteban; Carol Reynolds; Emily G Barr Fritcher; Marlene H Frost; Robert A Vierkant; Stephanie S Anderson; Amy C Degnim; Daniel W Visscher; V Shane Pankratz; Lynn C Hartmann
Journal:  Breast Cancer Res Treat       Date:  2009-09-23       Impact factor: 4.872

8.  Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.

Authors:  H Wong; S Lau; T Yau; P Cheung; R J Epstein
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

Review 9.  The hallmarks of premalignant conditions: a molecular basis for cancer prevention.

Authors:  Bríd M Ryan; Jessica M Faupel-Badger
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.